Drugs / Trivalent P2-VP8
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04658914 | Apr 2021 → Aug 2022 | Rotavirus infection, diarrheal disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| Phase 2 | NCT04344054 | Feb 2021 → Sep 2022 | Rotavirus infection | PATH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent P2-VP8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04658914 ↗ |
| Modality | Vaccine | “0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen” NCT04344054 ↗ |
| Route | Intramuscular | “A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.” NCT04658914 ↗ |